• Syntara completes A$10.0 million via a two-tranche placement at $0.022 per share.
  • The Company completes Share Purchase Plan (SPP) that provided all eligible shareholders the opportunity to participate in the transaction.
  • Funds raised will be used towards completion of three Phase 2 clinical trials in myelofibrosis, scarring and iRBD/Parkinson’s disease as well as for general working capital purposes and capital raising costs.

Read the media announcement here

Review the investor presentation here

Watch a Proactive interview with CEO Gary Phillips here

Read the notice of meeting to approve the second tranche here.

Read the share purchase plan booklet here.